David Arkadir

David Arkadir

Auto-generated profile, based on publicly available information

David Arkadir

Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 9124001, Israel

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2019 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
PRPnina Rappel
Pnina Rappel
SGShai Grosberg
Shai Grosberg
DADavid Arkadir
David Arkadir
ELEduard Linetsky
Eduard Linetsky
MSMuneer Abu Snineh
Muneer Abu Snineh
RERenana Eitan
Renana Eitan

19 November 2019 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
SESuaad Abd Elhadi
Suaad Abd Elhadi
JGJessica Grigoletto
Jessica Grigoletto
MPMaura Poli
Maura Poli
Paolo ArosioPaolo Arosio
Paolo Arosio
DADavid Arkadir
David Arkadir
RSRonit Sharon
Ronit Sharon
Objective: To determine whether blood cells expressed α‐Syn can differentiate Parkinson’s disease (PD) from healthy controls (HC).Methods: The concentrations of α‐Syn were determined in samples of blood cell pellets using a quantitative Lipid‐ELISA assay. In addition, the levels of total protein, hemoglobin, iron and H‐ferritin were determined. The study includes samples from the Biofind cohort (n = 46 PD and 45 HC) and results were validated with an additional cohort (n = 35 PD and 28 HC).Results: A composite biomarker consisting of the concentrations of total α‐Syn, proteinase‐K resistant (PKres) α‐Syn and phospho‐Serine 129 α‐Syn (PSer 129), is designed based on the analysis of the discovery BioFIND cohort. This composite biomarker differentiates a PD subgroup, presenting motor symptoms without dementia from a HC group, with a convincing accuracy, represented by an AUC = 0.81 (95% CI, 0.71 to 0.92). Closely similar results were obtained for the validation cohort, that is, AUC = 0.81, (95% CI, 0.70 to 0.94).Interpretation: Our results demonstrate the potential usefulness of blood cells expressed α‐Syn as a biomarker for PD.

23 February 2018 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
DADavid Arkadir
David Arkadir
TDTama Dinur
Tama Dinur
SRShoshana Revel‐Vilk
Shoshana Revel‐Vilk
MCMichal Becker Cohen
Michal Becker Cohen
CCClaudia Cozma
Claudia Cozma
Ari ZimranAri Zimran
Ari Zimran

15 November 2018 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
DADavid Arkadir
David Arkadir
ALAlexander Lossos
Alexander Lossos
DRDolev Rahat
Dolev Rahat
MSMuneer Abu Snineh
Muneer Abu Snineh
OSOra Schueler‐Furman
Ora Schueler‐Furman
VMVardiella Meiner
Vardiella Meiner
Objective: To investigate the genetic basis of the recessive form of primary familial brain calcification and study pathways linking a novel gene with known dominant genes that cause the disease.Methods: Whole exome sequencing and Sanger‐based segregation analysis were used to identify possible disease causing mutations. Mutation pathogenicity was validated by structural protein modeling. Functional associations between the candidate gene, MYORG, and genes previously implicated in the disease were examined through phylogenetic profiling.Results: We studied nine affected individuals from two unrelated families of Middle Eastern origin. The median age of symptom onset was 29.5 years (range 21–57 years) and dysarthria was the most common presenting symptom. We identified in the MYORG gene, a homozygous c.1233delC mutation in one family and c.1060_1062delGAC mutation in another. The first mutation results in protein truncation and the second in deletion of a highly conserved aspartic acid that is likely to disrupt binding of the protein with its substrate. Phylogenetic profiling analysis of the MYORG protein sequence suggests co‐evolution with a number of calcium channels as well as other proteins related to regulation of anion transmembrane transport (False Discovery Rate, FDR < 10−8) and with PDCD6IP, a protein interacting with PDGFRβ which is known to be involved in the disease.Interpretation: MYORG mutations are linked to a recessive form of primary familial brain calcification. This association was recently described in patients of Chinese ancestry. We suggest the possibility that MYORG mutations lead to calcification in a PDGFRβ‐related pathway.

12 November 2019 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
BYBrit Youngmann
Brit Youngmann
LALiron Allerhand
Liron Allerhand
OPOra Paltiel
Ora Paltiel
EYElad Yom-Tov
Elad Yom-Tov
DADavid Arkadir
David Arkadir
Objective: To develop, apply, and evaluate, a novel web‐based classifier for screening for Parkinson disease among a large cohort of search engine users.Methods: A supervised machine learning classifier learned to distinguish web users with self‐reported Parkinson's disease from controls based on their interactions with a search engine (Bing, Microsoft). It was then applied to groups of web users with low or high risk for actual Parkinson's disease. Textual content of web queries was used to sort surfers into the different risk groups, but not for classifying users as negative or positive for Parkinson's disease. Disease detection was unsolicited. Researchers did not have access to any identifying data on users.Results: Applying the classifier (with an estimated positive predictive value of 25%) resulted in 17,843/1,490,987 (1.2%) web users over the age of 40 years screened positive for Parkinson's disease. This percentile was higher in at‐risk groups (Fisher exact P < 0.00001), including users who searched for information regarding the disease (518/804, 64.4%), and users with non‐motor Parkinson's symptom or with an affected relative (57/1064, 5.3%). Longitudinal follow‐up revealed that in all studied groups individuals classified as having the disease showed a higher mean rate of progression in disease‐related features (t‐test P < 0.05).Interpretation: An automatic classifier, based on mouse and keyboard interactions with a search engine, is able to reliably trace individuals at high risk for actual Parkinson's disease as well as to demonstrate more rapid progression of disease‐related signs in those who screened positive. This ability raises novel ethical issues.

2 November 2023 in Movement Disorders
Verified
Journal Article
Open access
GPGian D. Pal
Gian D. Pal
DCDaniel M. Corcos
Daniel M. Corcos
LMLeo Verhagen Metman
Leo Verhagen Metman
ZIZvi Israel
Zvi Israel
HBHagai Bergman
Hagai Bergman
DADavid Arkadir
David Arkadir
Genetic subtyping of patients with Parkinson's disease (PD) may assist in predicting the cognitive and motor outcomes of subthalamic deep brain stimulation (STN‐DBS). Practical questions were recently raised with the emergence of new data regarding suboptimal cognitive outcomes after STN‐DBS in individuals with PD associated with pathogenic variants in glucocerebrosidase gene (GBA1‐PD). However, a variety of gaps and controversies remain. (1) Does STN‐DBS truly accelerate cognitive deterioration in GBA1‐PD? If so, what is the clinical significance of this acceleration? (2) How should the overall risk‐to‐benefit ratio of STN‐DBS in GBA1‐PD be established? (3) If STN‐DBS has a negative effect on cognition in GBA1‐PD, how can this effect be minimized? (4) Should PD patients be genetically tested before STN‐DBS? (5) How should GBA1‐PD patients considering STN‐DBS be counseled? We aim to summarize the currently available relevant data and detail the gaps and controversies that exist pertaining to these questions. In the absence of evidence‐based data, all authors strongly agree that clinicians should not categorically deny DBS to PD patients based solely on genotype (GBA1 status). We suggest that PD patients considering DBS may be offered genetic testing for GBA1, where available and feasible, so the potential risks and benefits of STN‐DBS can be properly weighed by both the patient and clinician. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.